STERIS plc (STE) Stock Price, News, Analysis

Technical Score (1D)

SELL

News Sentiment

BULLISH

STERIS (STE) is facing scrutiny following recent price weakness, with shares down significantly over the past one and three months, despite continued revenue and net income growth. This divergence suggests recent price action may be driven by shifting market sentiment rather than fundamental business changes, with the stock trading at a discount to its estimated fair value. While the Healthcare and Applied Sterilization Technologies segments show strong adoption and service revenue growth, macroeconomic volatilities and unfavorable foreign exchange rates present potential headwinds. Analysts at Argus Research have lowered their price target to $243.00, though they maintain a BUY rating, citing STE's strong industry standing and growth prospects. Looking at broader sector implications, the healthcare sector experienced unexpected job losses in February, raising concerns about potential economic slowdowns impacting healthcare spending. This broader market reaction contributed to STERIS's share decline. Investors should watch for continued execution of capital return strategies and any further commentary on macroeconomic factors and FX rates.

Market Data

STE Stock Snapshot

STERIS plc · Healthcare · steris.com

STERIS plc is a global provider of infection prevention solutions, serving the healthcare, pharmaceutical, and medical device industries. The company operates through three primary segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. STERIS's Healthcare segment offers a broad portfolio of products and services, including cleaning and sterilization equipment, accessories, and related services for hospitals and other healthcare facilities. Through AST, STERIS provides contract sterilization services and testing to medical device and pharmaceutical manufacturers, along with integrated sterilization equipment. The Life Sciences segment supplies consumable products, such as disinfectants and sterilants, and equipment for pharmaceutical and research applications, complemented by service offerings. Founded in 1985, STERIS is headquartered in Mentor, Ohio.

STE is currently trading at $221.50, giving STERIS plc a market cap of 21.99B and a P/E ratio of 31.1. Today's range spans $220.60–$226.52, with shares opening at $225.00 and moving up $0.00 (0.0%) from the prior close. DailyIQ's technical score sits at 41/100 (HOLD) with a news sentiment reading of 63/100.

Over the past year STE has traded between $209.98 and $269.44 - the current price is +5.5% off the 52-week low and -17.8% from the high. 16 analysts cover the stock with a Buy consensus and a mean 12-month target of $281.25 (range $231.00–$300.00), implying upside of +27.0%.

STERIS plc (STE) has 21.99B in Healthcare market capitalization and is currently neutral on the technical dashboard: 41/100, HOLD, price $221.50 (in the lower half of its 52-week range). Sentiment reads bullish at 63/100. (P/E: 31.1) In this tier, quiet accumulation often happens in HOLD phases - active managers who want to build positions without signaling do it here, where the price isn't trending and volume patterns are easier to hide. Annual range: $209.98–$269.44.

STE|EarningsSTERIS plc

Earnings Summary

STERIS plc is a global provider of infection prevention solutions, serving the healthcare, pharmaceutical, and medical device industries across its Healthcare, Applied Sterilization Technologies (AST), and Life Sciences segments. As a key player in the Healthcare sector, specifically within the Medical Devices industry, STERIS offers a comprehensive range of products and services aimed at enhancing safety and efficacy in critical environments. The company's business model encompasses equipment, consumables, and specialized sterilization services, positioning it as a vital partner for healthcare facilities and life science manufacturers. In its most recent reported quarters, STERIS demonstrated a mixed performance. For Q2 2025, the company reported actual EPS of $2.34 against an estimate of $2.26, and for Q3 2025, actual EPS was $2.47 against an estimate of $2.35. This indicates a pattern of beating analyst expectations on earnings in these two most recent periods, following a Q1 2025 beat of $2.74 actual versus $2.60 estimate. However, the Q4 2024 quarter saw a slight miss with actual EPS of $2.32 against an estimate of $2.32143. Revenue figures are available for Q4 2024 ($1.37 billion), Q1 2025 ($1.48 billion), and Q2 2025 ($1.39 billion), but direct comparisons to estimates are not possible as revenue estimates were not provided for these periods. Looking at the broader historical trajectory, STERIS has shown a consistent ability to grow its revenue year-over-year, even when facing challenges. The company has a track record of meeting or exceeding analyst expectations for earnings in several recent quarters, though the Q4 2024 EPS was very close to the estimate. Recent news indicates that STERIS has experienced underperformance relative to its peers and the broader market, with its stock declining significantly from its 52-week high despite continued revenue and net income growth. Analysts maintain a cautiously optimistic view, with some lowering price targets while maintaining buy ratings, citing factors like underperforming return on capital and director share sales. However, significant institutional buying, such as by Mitsubishi UFJ Asset Management, suggests growing confidence. Investors will be watching for STERIS's ability to regain relative performance against its peers and for any further developments regarding analyst sentiment and valuation in the upcoming quarters, especially in light of its market leadership and durable growth profile.

Earnings | EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q3'26	$2.56	-	-
Q3'25	$2.35	$2.47	+5.1%
Q2'25	$2.26	$2.34	+3.4%
Q1'25	$2.60	$2.74	+5.4%
Q4'24	$2.32	$2.32	-0.1%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q3'26	$1.5B	-	-
Q3'25	-	$1.5B	-
Q2'25	-	$1.4B	-
Q1'25	-	$1.5B	-
Q4'24	-	$1.4B	-

Technical Score (1D)

SELL

News Sentiment

BULLISH

Market Data

STE Stock Snapshot

STERIS plc · Healthcare · steris.com

News Sentiment Analysis

Sentiment gathered from recent headlines

63/100

Strong NegativeNeutralStrong Positive

MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

Argus Research has increased its price target for STE to $247.00, reflecting a positive assessment of the company's prospects. This upward revision suggests continued confidence from analysts in STE's future performance and market position. Investors should monitor any further commentary from Argus regarding the specific drivers behind this target adjustment.

What did this article say?

STERIS PLC demonstrates key characteristics of quality investing, highlighted by its impressive revenue expansion and efficient capital allocation. The company's solid financial foundation, including a robust balance sheet, positions it favorably for sustained long-term performance. These metrics suggest a well-managed business attractive to value-oriented investors.

What did this article say?

STERIS (STE) shares have experienced recent short-term price weakness, including a 90-day decline of 12.88%. However, longer-term returns remain positive, suggesting current price action may reflect shifting market sentiment rather than fundamental business changes. Despite recent volatility, the company shows revenue and net income growth, with an estimated intrinsic discount and a gap to analyst targets, indicating potential undervaluation.

What did this article say?

Teleflex has advanced its previously announced share repurchase program, indicating a proactive approach to returning capital to shareholders. This accelerated buyback suggests management's conviction in the company's intrinsic value and future prospects. Investors will be watching for continued execution and any further capital allocation strategies.

What did this article say?

STERIS's Healthcare segment demonstrates robust market adoption of its infection prevention consumables and capital equipment, contributing to positive organic growth. The Applied Sterilization Technologies segment also benefits from strong service revenues. However, macroeconomic volatilities and unfavorable foreign exchange rates present potential headwinds for the company. Despite a recent share price decline, STE's earnings yield remains favorable compared to its industry peers.

What did this article say?

STERIS (STE), a provider of infection prevention and sterilization solutions for healthcare and life sciences, is highlighted as a stock facing challenges. The article points to a Return on Invested Capital (ROIC) of 5% as an indicator of management's difficulty in finding compelling investment opportunities. This metric suggests potential headwinds for the company's ability to generate strong returns from its capital deployment.

What did this article say?

Starr Peak Mining Ltd. (STE) is advancing exploration with plans for a follow-up drill program targeting a high-potential BHEM anomaly at Normetmar. This deep target is situated below existing mineralization and approximately 900 meters west of the historical Normétal Mine. The initiative leverages previous BHEM investigation results to potentially unlock new copper resources.

What did this article say?

Argus Research has reduced its price target for STE to $243.00. This adjustment reflects a recalibration of valuation metrics by the analyst firm. Investors should monitor the company's upcoming earnings reports and strategic initiatives for potential shifts in performance.

What did this article say?

Steris PLC (STE) experienced underperformance relative to its peers on Wednesday. This trading action suggests potential headwinds or specific company-level factors impacting its stock. Investors should monitor STE's relative performance against industry benchmarks.

What did this article say?

Steris PLC (STE) demonstrated strong performance, outperforming its competitors during a robust trading day. This upward momentum indicates positive investor sentiment or favorable company-specific developments. Traders should observe if this outperformance is sustained.

STE|EarningsSTERIS plc

Earnings Summary

Earnings | EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q3'26	$2.56	-	-
Q3'25	$2.35	$2.47	+5.1%
Q2'25	$2.26	$2.34	+3.4%
Q1'25	$2.60	$2.74	+5.4%
Q4'24	$2.32	$2.32	-0.1%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q3'26	$1.5B	-	-
Q3'25	-	$1.5B	-
Q2'25	-	$1.4B	-
Q1'25	-	$1.5B	-
Q4'24	-	$1.4B	-

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

STE·STERIS plc

STE Stock Snapshot

Earnings | EPS

Revenue

STE·STERIS plc

STE Stock Snapshot

News Sentiment Analysis

Recent News Coverage

Earnings | EPS

Revenue

News Sentiment Analysis

Recent News Coverage

STE·STERIS plc

STE Stock Snapshot

Earnings | EPS

Revenue

STE·STERIS plc

STE Stock Snapshot

News Sentiment Analysis

Recent News Coverage

Earnings | EPS

Revenue

Discover More

News Sentiment Analysis

Recent News Coverage

Discover More